AI + MedicineAI now helps find drug targets, predict protein shapes and design molecules. But most drugs fail in clinical trials because they don't work well enough or are too toxic, and AI hasn't yet shown it can change that.
BreakthroughsKilling diseased cells in a dish is the easy part of drug development. This guide explains the evidence ladder, why most candidates fail, and seven questions to ask before believing a breakthrough headline.
LongevityLongevity claims are everywhere, but human evidence is thin. This field guide sorts the most popular anti-ageing ideas by what has been shown in animals, what has been tested in people, and what nobody knows yet.
BreakthroughsA positive Phase 1 result and a positive Phase 3 result sound similar but mean very different things. Here is what each stage of a clinical trial is designed to show, and what it cannot.
Companies + StocksMany biotech startups spend years building evidence rather than selling products. This map traces the stations most pass through, from licensing a discovery to the forks where companies partner, sell, go public or stop.
Companies + StocksBiotech companies tell two stories at once: one scientific, one financial. This educational guide, which is not investment advice, shows how to check primary sources like SEC EDGAR, ClinicalTrials.gov and FDA databases.
Companies + StocksMost medical products begin as university research, then pass through tech transfer offices, licences or spinouts, and the regulatory system. This guide maps each step and the reasons discoveries stall.